Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South…
Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (United States, France, Germany, Italy,…
Clarivate Epidemiology’s coverage of chronic fatigue syndrome (CFS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of chronic fatigue syndrome (CFS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Clarivate Epidemiology’s coverage of generalized anxiety disorder (GAD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States,…
DRG Epidemiology’s coverage of social anxiety disorder (SAD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for each…
Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for each…
Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for each…
Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for each…
Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for each…
DRG Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany,…
The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primarily effective in treating positive symptoms. However, in late 2019, the U.S…